Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apremilast for Nail Psoriasis
NCT03022617Phase 4Completed
- Sponsor
- University of Alabama at Birmingham
- Start
- Jan 2017
- Primary completion
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of apremilast in nail psoriasis, sponsored by University of Alabama at Birmingham. Primary endpoint: Mean Percent Change of Modified Nail Area Psoriasis Severity Index at 36 weeks. Started Jan 2017; status: completed.
02
Drugs
apremilast
03
Conditions
nail psoriasis
Beyond the preview
Go deeper on NCT03022617.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03022617.